Tag Archives: oral beta secretase cleaving enzyme (BACE)

AstraZeneca and Eli Lilly to enrol more than 1,500 patients in 15 countries to their Phase II/III study of oral beta secretase cleaving enzyme (BACE) inhibitor in development as potential treatment for Alzheimer’s disease

Posted on 2, December 2014 by

Phase II/III trial of AZD3293, an oral potent small molecule inhibitor of BACE, aims to enrol more than 1,500 patients in 15 countries LONDON, 2-12-2014 — /EuropaWire/ — AstraZeneca and Eli Lilly and Company (Lilly) today announced enrolment of the … Read the full press release →

Posted in Healthcare, Pharma & Biotech, United Kingdom

Tagged , , , , ,